Report Highlights
The global market for monoclonal antibodies in oncology is expected to grow from $129.3 billion in 2025 and is projected to reach $228 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12% during the forecast period of 2025 to 2030.
Report Includes
- 91 data tables and 59 additional tables
- In-depth analysis of the global markets for monoclonal antibodies (mAbs) for oncology
- Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
- Estimates of the current market size and revenue prospects for the global market, along with a corresponding market share analysis based on type, cancer type and region
- Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, prospects and the impact of macroeconomic variables
- Highlights of promising new advancements in monoclonal antibody-based nanoparticle therapy in cancer treatment, the emergence of next-generation therapeutic inhibitors, their potential and mechanism of action
- Insights derived from Porter’s Five Forces model, as well as global supply chain analyses
- Review of the regulatory landscape featuring the U.S. premarket notifications and approvals with emphasis on recently approved products as well as products under development or in different stages of clinical trials
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- A relevant patent analysis, featuring key granted and published patents
- Analysis of the industry structure, including companies’ market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Co., Johnson & Johnson Services, AstraZeneca, and Amgen Inc.
Report Scope
The report provides detailed information on monoclonal antibodies in oncology. This report analyzes the market trends and includes global revenue ($ million) for the base year 2024, estimated data for 2025, and forecast data from 2025 through 2030. The report highlights the current and future market potential of monoclonal antibodies in oncology and provides a detailed analysis of the competitive environment. It includes regulatory scenarios, drivers, restraints and opportunities, as well as market projections for 2030 and the market share for key companies.
The market scope in this report is segmented by type, cancer type and region. By type, the market is segmented into humanized, human and chimeric. The cancer type segment is characterized into lung cancer, breast cancer, colorectal cancer, lymphoma, leukemia, melanoma, multiple myeloma and other cancers.
The region covered in this study includes North America, Europe, Asia-Pacific, the Middle East and Africa (MEA) and South America. The regional segment provides a detailed analysis of major countries, including the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia and India.
The report aims to:
- Analyze types of monoclonal antibodies in oncology.
- Analyze global market size and segmentation.
- Understand market constraints and drivers.
- Provide detailed market forecasts through 2030.
- Assess market shares, competitiveness and industry structure.
- Identify potential long-term impacts on the market for monoclonal antibodies in oncology.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2024 | ||||||||||||||||
| Forecast period considered | 2025-2030 | ||||||||||||||||
| Base year market size | $116.4 Billion | ||||||||||||||||
| Market size forecast | $228 Billion | ||||||||||||||||
| Growth rate | CAGR of 12% for the forecast period of 2025-2030 | ||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||
| Segments covered | Type, Cancer Type, and Region | ||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, South America and Middle East and Africa | ||||||||||||||||
| Countries covered | U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, and Argentina | ||||||||||||||||
| Key Market Drivers |
|
||||||||||||||||
| Companies studied |
|
||||||||||||||||
Frequently Asked Questions (FAQs)
- Acceleration in Cancer Rates
- Unmet Treatment Need and the Role of Monoclonal Antibodies in Oncology
- Increasing R&D Spending by Market Players
- Rise in Government Funding and Pharmaceutical R&D Spending.
- High Cost of Monoclonal Antibodies
- Loss of Exclusivity and Genericization
- Shortage of Oncology Professionals
- Potential of Monoclonal Antibodies in Oncology
- Emerging Markets
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Consulting Editor’s Credentials
Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.
Related Reports
Immunotherapy Drugs: Global Markets
The global immunotherapy drugs market is expected to grow from $260.7 billion in 2025 and is projected to reach $467.4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% during the forecast period of 2025 to 2030.
Biological Therapies for Cancer: Technologies and Global Markets
The global biological therapies market for cancer is expected to grow from $157 billion in 2025 and is projected to reach $225 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2025 to 2030.
Brain Tumor Therapeutics: Global Markets to 2030
The report provides an analysis of brain tumor therapeutics and analyzes market trends. Using 2024 as the base year, the report provides estimated market data for 2025 through 2030. The market in this report is segmented by therapy type, patient age, end user, and region. The report covers regulatory scenarios, drivers, restraints, opportunities, and the market share for key companies.
Cancer Immunotherapy: Technologies and Global Markets
The global cancer immunotherapy market is expected to grow from $144.2 billion in 2024 and is projected to reach $247.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2024 to 2029.
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Neuroprotective Agents: Therapeutic Applications and Global Markets
The global market for neuroprotective agents is expected to grow from $43.9 billion in 2025 and is projected to reach $60.9 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.7% during the forecast period of 2025 to 2030.
Radioligand Therapeutics in Cancer Treatment: Global Markets
The global market for radioligand therapeutics in cancer treatment is estimated to grow from $2.6 billion in 2025 to $4.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.1% from 2025 through 2030.
Monoclonal Antibodies for Oncology: Global Markets
The global market for monoclonal antibodies in oncology is expected to grow from $129.3 billion in 2025 and is projected to reach $228 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12% during the forecast period of 2025 to 2030.
Cannabis Market: Products, Technologies, and Applications
The global market for cannabis was valued at $45.6 billion in 2025 and is projected to reach $79.3 billion by the end of 2030, at a compound annual growth rate (CAGR) of 11.7% during the forecast period of 2025 to 2030.
Global Oncology Biosimilars Market
The global market for oncology biosimilars is estimated to grow from $9.6 billion in 2025 and projected to reach $17.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.6% from 2025 to 2030.
Top Trending Reports
Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing
The global market for genetic modification therapies is estimated to grow from $14.8 billion in 2025 to reach $32.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 16.8% from 2025 through 2030.
State of the Life Sciences Industry - Fourth Quarter Review
State of the Life Sciences Industry Market Report delivers insights on biotech, pharma, medical devices, innovation trends, and global market outlook.
Carbon Fiber: Global Markets
The global market for carbon fiber was valued at $4.9 billion in 2024 and is estimated to increase from $5.3 billion in 2025 to reach $8.2 billion by 2030, at a compound annual growth rate (CAGR) of 9.1% from 2025 through 2030.
Global Markets for Diabetes Therapeutics and Diagnostics
The global market for diabetes therapeutics and diagnostics is estimated to grow from $134.9 billion in 2025 to reach $241.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% from 2025 through 2030.
Sleep Aids: Technologies and Global Markets
The global market for sleep aid technologies is estimated to grow from $103.5 billion in 2025 to reach $136 billion by 2030, at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2030.
Report Highlights
The global market for monoclonal antibodies in oncology is estimated to grow from $76.2 billion in 2022 to more than $138.1 billion by 2027, with a compound annual growth rate (CAGR) of 12.6% during the forecast period of 2022-2027.
Report Includes
- 25 data tables and 24 additional tables
- A brief general outlook of the global monoclonal antibodies for oncology market
- Analyses of the global market trends, with market revenue (sales data) for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the current and future market potential of monoclonal antibodies for oncology treatment, and areas of focus to forecast this market into various segments and sub-segments
- Evaluation of the actual market size for monoclonal antibodies in oncology treatment, forecasted growth trends, and corresponding market share analysis by type of antibody, application area, and region
- Technology assessment of the key drivers, restraints and opportunities that will shape the market over the next five years (2022 to 2027)
- In-depth information on increasing investments on R&D activities, key technology issues, industry specific challenges, major types of end-user markets, and COVID-19 implications on the progress of this market
- Review of the patent landscape and new developments in the market for monoclonal antibodies for oncology and associated clinical trials
- Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
- Company profiles of major players within the industry, including AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc. and Pfizer Inc.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More